Takeshi Tsugawa

Dr. Takeshi Tsugawa

orcid

Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2021 in Journal of Infection and Chemotherapy
Verified
Journal Article
Closed access
YFYuya Fukuda
Yuya Fukuda
TTTakeshi Tsugawa
Takeshi Tsugawa
YNYoshinobu Nagaoka
Yoshinobu Nagaoka
AIAkira Ishii
Akira Ishii
TNTomohiro Nawa
Tomohiro Nawa
YKYukihiko Kawasaki
Yukihiko Kawasaki

1 June 2017 in Emerging Infectious Diseases
Verified
Journal Article
Open access
KKKenji Kondo
Kenji Kondo
TTTakeshi Tsugawa
Takeshi Tsugawa
MOMayumi Ono
Mayumi Ono
TOToshio Ohara
Toshio Ohara
SFShinsuke Fujibayashi
Shinsuke Fujibayashi
HTHiroyuki Tsutsumi
Hiroyuki Tsutsumi
During March–July 2014, rotavirus G8P[8] emerged as the predominant cause of rotavirus gastroenteritis among children in Hokkaido Prefecture, Japan. Clinical characteristics were similar for infections caused by G8 and non-G8 strains. Sequence and phylogenetic analyses suggest the strains were generated by multiple reassortment events between DS-1–like P[8] strains and bovine strains from Asia.

15 May 2014 in Journal of Virology
Verified
Journal Article
Open access
PDF file
TTTakeshi Tsugawa
Takeshi Tsugawa
MTMasatoshi Tatsumi
Masatoshi Tatsumi
HTHiroyuki Tsutsumi
Hiroyuki Tsutsumi
Although significant clinical efficacy and safety of rotavirus vaccines were recently revealed in many countries, the mechanism of their attenuation is not well understood. We passaged serially a cell culture-adapted murine rotavirus EB strain in mouse pups or in cell cultures alternately and repeatedly and fully sequenced all 11 genes of 21 virus samples passaged in mice or in cell cultures. Sequence analysis revealed that mouse-passaged viruses that regained virulence almost consistently acquired four kinds of amino acid (aa) substitutions in VP4 and substitution in aa 37 (Val to Ala) in NSP4. In addition, they gained and invariably conserved the 3′ consensus sequence in NSP1. The molecular changes occurred along with the acquisition of virulence during passages in mice and then disappeared following passages in cell cultures. Intraperitoneal injection of recombinant NSP4 proteins confirmed the aa 37 site as important for its diarrheagenic activity in mice. These genome changes are likely to be correlated with rotavirus virulence.IMPORTANCESerial passage of a virulent wild-type virusin vitrooften results in loss of virulence of the virus in an original animal host, while serial passage of a cell culture-adapted avirulent virusin vivooften gains virulence in an animal host. Actually, live attenuated virus vaccines were originally produced by serial passage in cell cultures. Although clinical efficacy and safety of rotavirus vaccines were recently revealed, the mechanism of their attenuation is not well understood. We passaged serially a murine rotavirus by alternating switch of host (mice or cell cultures) repeatedly and sequenced the eleven genes of the passaged viruses to identify mutations associated with the emergence or disappearance of virulence. Sequence analysis revealed that changes in three genes (VP4, NSP1, and NSP4) were associated with virulence in mice. Intraperitoneal injection of recombinant NSP4 proteins confirmed its diarrheagenic activity in mice. These genome changes are likely to be correlated with rotavirus virulence.

20 October 2020 in Microorganisms
Verified
Journal Article
Open access
PDF file
MSMitsuru Sada
Mitsuru Sada
Takeshi SarayaTakeshi Saraya
Takeshi Saraya
HIHaruyuki Ishii
Haruyuki Ishii
KOKaori Okayama
Kaori Okayama
YHYuriko Hayashi
Yuriko Hayashi
Hirokazu KimuraHirokazu Kimura
Hirokazu Kimura
Favipiravir was initially developed as an antiviral drug against influenza and is currently used in clinical trials against severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection (COVID-19). This agent is presumably involved in RNA chain termination during influenza virus replication, although the molecular interactions underlying its potential impact on the coronaviruses including SARS-CoV-2, SARS-CoV, and Middle East respiratory syndrome coronavirus (MERS-CoV) remain unclear. We performed in silico studies to elucidate detailed molecular interactions between favipiravir and the SARS-CoV-2, SARS-CoV, MERS-CoV, and influenza virus RNA-dependent RNA polymerases (RdRp). As a result, no interactions between favipiravir ribofuranosyl-5′-triphosphate (F-RTP), the active form of favipiravir, and the active sites of RdRps (PB1 proteins) from influenza A (H1N1)pdm09 virus were found, yet the agent bound to the tunnel of the replication genome of PB1 protein leading to the inhibition of replicated RNA passage. In contrast, F-RTP bound to the active sites of coronavirus RdRp in the presence of the agent and RdRp. Further, the agent bound to the replicated RNA terminus in the presence of agent, magnesium ions, nucleotide triphosphate, and RdRp proteins. These results suggest that favipiravir exhibits distinct mechanisms of action against influenza virus and various coronaviruses.

17 August 2022 in Microorganisms
Verified
Journal Article
Open access
PDF file
MSMitsuru Sada
Mitsuru Sada
Hirokazu KimuraHirokazu Kimura
Hirokazu Kimura
NNNorika Nagasawa
Norika Nagasawa
MAMao Akagawa
Mao Akagawa
KOKaori Okayama
Kaori Okayama
KMKoichi Murakami
Koichi Murakami
DNA gyrase plays important roles in genome replication in various bacteria, including Pseudomonasaeruginosa. The gyrA gene encodes the gyrase subunit A protein (GyrA). Mutations in GyrA are associated with resistance to quinolone-based antibiotics. We performed a detailed molecular evolutionary analyses of the gyrA gene and associated resistance to the quinolone drug, ciprofloxacin, using bioinformatics techniques. We produced an evolutionary phylogenetic tree using the Bayesian Markov Chain Monte Carlo (MCMC) method. This tree indicated that a common ancestor of the gene was present over 760 years ago, and the offspring formed multiple clusters. Quinolone drug-resistance-associated amino-acid substitutions in GyrA, including T83I and D87N, emerged after the drug was used clinically. These substitutions appeared to be positive selection sites. The molecular affinity between ciprofloxacin and the GyrA protein containing T83I and/or D87N decreased significantly compared to that between the drug and GyrA protein, with no substitutions. The rate of evolution of the gene before quinolone drugs were first used in the clinic, in 1962, was significantly lower than that after the drug was used. These results suggest that the gyrA gene evolved to permit the bacterium to overcome quinolone treatment.

1 July 2021 in Journal of Infection and Chemotherapy
Verified
Journal Article
Closed access
TTTakeshi Tsugawa
Takeshi Tsugawa
YAYusuke Akane
Yusuke Akane
SHSaho Honjo
Saho Honjo
KKKenji Kondo
Kenji Kondo
YKYukihiko Kawasaki
Yukihiko Kawasaki